Summary
Boston Scientific Corporation's (BSX) third quarter and first nine months of 2019 results show significant growth, largely driven by the strategic acquisition of BTG plc. Net sales increased by 13.1% in Q3 2019 and 7.8% year-to-date, with strong operational growth across most business segments, particularly Urology & Pelvic Health and Neuromodulation. The company reported a net income of $126 million for Q3 2019, down from $432 million in the prior year, impacted by acquisition-related charges and other expenses. However, when excluding these one-time items, adjusted net income demonstrated resilience. The company's balance sheet reflects a substantial increase in assets, largely due to goodwill and intangible assets arising from acquisitions, notably BTG. Total debt also increased significantly, primarily to fund acquisitions. Despite increased leverage, the company remains compliant with its debt covenants. Management expresses confidence in its liquidity and ability to fund ongoing operations and strategic initiatives. Investors should note the significant impact of acquisitions on the company's financial statements, including increased goodwill, intangible assets, and debt. While overall sales growth is positive, the net income decrease in reported figures highlights the importance of analyzing non-GAAP adjusted figures to understand underlying operational performance. The company's integration of BTG and continued focus on innovation across its diverse medical device portfolio are key areas to monitor.
Financial Highlights
51 data points| Revenue | $2.71B |
| Cost of Revenue | $777.00M |
| Gross Profit | $1.93B |
| SG&A Expenses | $1.01B |
| Operating Expenses | $1.55B |
| Operating Income | $383.00M |
| Interest Expense | $95.00M |
| Net Income | $126.00M |
| EPS (Basic) | $0.09 |
| EPS (Diluted) | $0.09 |
| Shares Outstanding (Basic) | 1.39B |
| Shares Outstanding (Diluted) | 1.41B |
Key Highlights
- 1Net sales increased by 13.1% to $2.707 billion in Q3 2019 and by 7.8% to $7.831 billion in the first nine months of 2019, driven by strong operational growth and acquisitions.
- 2The acquisition of BTG plc (completed August 19, 2019) significantly impacted financial results, contributing $71 million in net sales for Q3 2019 and adding substantial goodwill and intangible assets.
- 3Reported net income decreased to $126 million ($0.09/share) in Q3 2019 from $432 million ($0.31/share) in Q3 2018, primarily due to significant acquisition-related charges, amortization, and litigation expenses.
- 4Adjusted net income (excluding certain charges) was $550 million ($0.39/share) in Q3 2019, compared to $485 million ($0.35/share) in Q3 2018, indicating strong underlying operational performance.
- 5Total debt increased significantly to $10.888 billion as of September 30, 2019, from $7.056 billion as of December 31, 2018, largely to finance acquisitions.
- 6Operating cash flow improved substantially, increasing to $1.144 billion in the first nine months of 2019, from $291 million in the prior year period.
- 7Key growth drivers included the Urology and Pelvic Health (up 18.6% in Q3) and Neuromodulation (up 17.5% in Q3) segments.